LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS)...
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS )
Also on site :
- NYT Mini Crossword Answers, Hints for Friday, June 20, 2025
- Canadian rescuers rush to a remote part of Banff park following reports that a rock slide hit hikers
- Country 'MVP' Refunds Entire Audience Mid-Concert and Fans 'Cannot Believe He Did That'